Abstract

Drug researchers are currently studying the use of nanoparticles in drug delivery in great detail. In general, a medication's pharmacokinetic and tissue appropriation profiles can be changed, intracellular infiltration and appropriation can be improved, and a drug's absorption can be improved by dispersing the drug via the epithelium. The ability of nanoparticulate frameworks to tolerate physiological pressure—that is, their increased organic stability and oral conveyance plausibility—is one of their key advantages. As such, they offer a more appealing drug delivery solution than liposomes.

Key Words

Nanoparticles, Pharmacokinetic, Intracellular Infiltration, Liposomes

Introduction

Furthermore, managing the surface characteristics, organisation, and milieu can result in the best possible pharmaceutical delivery example and its bio dispersion (Suri et al, 2007; Roco, 2003; Torchilin, 2008). Moreover, one notable benefit of nanoparticulate frameworks is their resistance to physiological pressure; however, they also show enhanced organic stability and oral delivery plausibility, which makes them a more appealing drug delivery option than liposomes (Sahoo & Labhasetwar, 2008; Couvreur & Vauthier, 2006; Kumar, 2000). 

Numerous nano-sized transporters, including polymeric nanoparticles, strong lipid nanoparticles, ceramic nanoparticles, attractive nanoparticles, polymericmicelles, polymer-drug forms, nanotubes, nanowires, nanocages, and dendrimers, are being developed for a range of drug delivery applications (Sahoo et al., 2007). Polymeric nanoparticles can be synthesised using synthetic polymers (Fattal et al., 1998; Breunig et al., 2008), polysaccharides (Liu et al., 2008; Fernandez-Urrusuno et al., 1999), or proteins (Farrugia & Groves, 1999).

Nanoparticles produced from naturally hydrophilic polymers have been shown to have enhanced drug loading capacity, biocompatibility, and perhaps reduced opsonization by the reticuloendothelial system (RES) through an aqueous steric barrier (Liu et al., 2008). Protein-based systems have been researched for the delivery of bioactives, nutrition, and medication. Casein, albumin, whey protein, and collagen are a few examples of these systems. Probiotic species and peptides; Kuijpers et al., 2000; Elzoghby et al., 2011). Proteins are a great source of raw materials. Materials, as they provide the benefits of synthetic polymers with absorbability and low degrading toxicity (Vandelli et al, 2001: Sahin et al, 2002) end goods. 

Protein-based nanoparticles are particularly noteworthy among the various colloidal drug carrier systems that are presently being developed because of their benefits, which include enhanced stability during storage and in vivo. They are non-toxic and non-antigenic, and they are simpler to create than other drug delivery techniques (Langer et al., 2003; Rubino et al., 1993; Kommareddy & Amiji, 2005; Azarmi et al., 2006). It has been demonstrated that albumin is a desirable macromolecular carrier that is non-toxic, biodegradable, immunogenic-negative, readily purified, and soluble in water. Due to these characteristics, it's a fantastic choice for injectable nanoparticle synthesis (Kratz et al., 1993; Rahimnejad et al., 2006).

The most prevalent protein in plasma, albumin is most recognised for its ability to bind to other proteins and for controlling lipid metabolism and vascular oncotic strain. To bind and transport several metabolites (Fasano et al, 2005; Quinlan et al, 2005). A plasma-derived product called therapeutic human serum albumin (HSA) is used to treat hypovolaemic shock, burn therapy, hypoproteinemia, and a number of other illnesses (Tullis, 1997; Tullis, 1977). Apart from its widely recognised characteristics, HSA has been demonstrated to elevate glutathione levels in peripheral blood cells (Cantin et al., 2000), a tripeptide essential for regular operation.immunological reactions in cells, lymphocytes, and humour (Droge et al., 1994). Conversely, HSA directly affects the management of Thus far, no on the other hand, HSA directly impacts the administration of It seems that this abundant plasma protein is not interfering with the actions of immune cells, since no immunological processes have been found to date. Furthermore, therapeutic preparations of HSA are commonly used as a negative control protein in research labs examining the immunomodulatory effects of therapeutic proteins like IVIg (Stohl & Elliot, 1996; Modiano et al, 1997; Crow et al, 2001; Grandmont et al, 2003; Tha-In et al, 2007; Ephrem et al, 2008)

Bovine serum albumin, human serum albumin, and ovalbumin are the three kinds of albumin. Among these is ovaalbumin, a monomeric phosphoglycoprotein. A lot of people eat it (Elsadek & Kratz, 2012). This multifunctional protein is composed of 385 protein units or amino acids. Its molecular structure includes four free sulfydryl groups and a disulfide link. The equivalent values for its molecular weight and isoelectric point are 4.8 Da and 47,000 Da, respectively (Oakenfull et al, 1997). Ovalbumin is used as a drug delivery technique, particularly in controlled drug delivery, because of its numerous desirable properties, including low cost, ease of availability, capacity to form gel networks, emulsion stabilisation, and pH- and temperature-sensitivity. Due to its affordability, medicinal value, natural abundance, and ease. Its mass is 69,323 Da and its density is 4.7 in water (at molecular weight and isoelectric point, 25OC) (Oakenfull et al, 1997). Instead of using bovine serum albumin, a human serum albumin replacement was utilised to prevent any potential in vivo immunologic reaction. Blood albumin is utilised. It is the most plentiful. A hydrophilic plasma protein with an extended half-life It has a half-life of 19 days and a molecular weight of 66,500 Da. According to Hirose et al. (2010), it contains 35 cysteinyl moieties, 17 disulfide bridges, and a sulfhydryl group.

A plasma protein with numerous uses is albumin. This protein is the main modulator of plasma oncotic pressure. Apart from that, there have been some oncotic changes. Pressure may be the source of the activation of HSA synthesis. Its tertiary structure allows it to bind to a wide range of compounds. These molecules include gases, metabolites, and foreign compounds such as medications. The sole mechanism for loaded HSA endocytosis that is thought to occur is receptor-mediated endocytosis; no evidence of an HSA receptor has been found. Additionally, it functions as a chaperone molecule, helping to fold proteins and avoiding the formation of new ones in disease-related aggregated proteins (Kragh-Hansen, 2013; Elzoghby et al, 2012; Sleep, 2015). The plasma that makes up the HSA is exposed to many types of oxidative stressors. The anti-oxidant function of this protein is well recognised; it aids in maintaining a fluid balance between compartments and restoring COP (Liumbruno et al, 2009). Treatment for hypoalbuminemia entails injecting 5 per cent, 20 per cent, or 25 per cent albumins that have been sterilised against viral infections for 10 to 11 hours at 60 to 0.5°C. The deactivation procedure. This sterilisation process is anticipated to produce denatured HSA (Kragh-Hansen et al., 2006; Dugaiczyk et al., 1982; Gerety & Aronson, 1982; Fanali et al., 2007). Treatment for hypoalbuminemia entails injecting 5 per cent, 20 per cent, or 25 per cent albumins that have been sterilised against viral infections for 10 to 11 hours at 60 to 0.5°C. The deactivation procedure. This sterilisation process is anticipated to produce denatured HSA (Kragh-Hansen et al., 2006; Dugaiczyk et al., 1982; Gerety & Aronson, 1982; Fanali et al., 2007). Clinical indications for albumin 4-5% solution include acute liver failure, cardiac bypass, and emergency therapy of hypovolemic shock. Fluids high in protein are confined (Tulisllis, 1977; Clowes et al, 1966). Many applications of albumin exist in the relevant field of research, such as supplementing cells, stabilising proteins, and cryopreservation. In a unique HSA application, peptides, a drug nanocarrier, and an oxygen transporter are combined ((Chen et al, 2013; Raoufinia et al, 2016; He et al, 2011).




Albumin Market

The albumin market is expected to increase at a compound yearly growth rate of 9.6% from its 2016 worth of $5,381 million to $10,305 million by 2023. The most concentrated protein in blood plasma is called albumin. It performs several tasks, including maintaining oncotic strain and facilitating the passage of hormones and fatty acids. It is used to replace lost fluid and assist in restoring blood volume in the treatment of wounds, burns, operations, infections, and liver problems. It increases the stability of medications by reducing oxidation, aggregation, and surface absorption. Serum albumin comes in a variety of forms that are commonly used in medical settings. 

Human serum albumin is made from human plasma, while bovine serum albumin is made from cow plasma. Conversely, recombinant albumin is produced in yeast and bacterial strains via recombinant techniques. The global albumin market is divided into three segments: commodity, application, and region. Recombinant albumin, bovine serum albumin, and human serum albumin are the three types of albumin that are available. Due to the product's large production, the human serum albumin category held the largest market share in 2016. This is expected to be the continuing pattern throughout the remainder of the projection. However, the recombinant albumin component is predicted to increase at a noteworthy CAGR of 11.4 per cent throughout the course of the projected period. 

The market is divided into four regions: North America, Europe, Asia-Pacific, and The Caribbean and Latin America. North America and Europe had the largest market shares in 2016. In contrast, Asia-Pacific is anticipated to lead the market over the projection period because of its sizable patient base, growing disposable income, and improved awareness of albumin products. (Srivastava & Jaiswal, 2018) 

Albumin Purification

Precipitation Using Ammonium Sulfate Salt

3 ml of produced serum was precipitated drop by drop into 3 ml of saturated ammonium sulphate on a magnetic stirrer. The mixture was then incubated at 4°C for a whole night. The pellet was soaked in water before cleaning. Five times saturated ammonium sulphate. For a full day at 4°C, the precipitate was dialyzed against Tris phosphate buffer (pH: 8.2) and PBS (pH: 7.2). The anti-HSA IgG was subsequently purified using ion exchange chromatography (Raoufinia et al, 2016). 




Albumin Purification using GFC

For condensation fractions up to fifty per cent, Amicon was utilised. The pH of the solution was adjusted to 5/2 by adding 1 M NaOH. The mixture was allowed to settle at 55°C for three hours before being cooled to 4°C overnight. also centrifuged for 20 minutes at 5000 xg. The albumin-containing solution's pH was raised to 6 using 1 M NaOH. The solution was put into a Sepharose G-100 gel filtration column (Raoufinia et al, 2018). 




Electrophoresis Analysis

The purity of various chromatographic fractions was evaluated in less restrictive conditions using cellulose acetate membrane electrophoresis (CAME) and sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). A 70 x 130 mm cellulose acetate membrane that was ready for CAME was used as the cathode area for the samples. For the electrophoresis, a continuous current of 0.7 mA/cm of membrane barbital buffer (pH 8.6, 0.05 mol/L sodium barbital) was employed for 20 minutes. On a 12 per cent gel, SDS-PAGE was performed at a steady voltage. Coomassie blue staining allowed for the visibility of the protein bands (Raoufinia et al., 2016). 




Affinity Chromatography

Liquid chromatography known as affinity chromatography uses affinity ligands, which are biological agents, as the stationary phase in the column. This strategy aims to purify analytics selectively and investigate biological interactions between molecules (Hag et al., 2012; Abdolalizadeh et al., 2013; Abdolalizadeh et al., 2012). Affinity chromatography was first developed for purification in 1968 (Cuatrecasas et al., 1968). 




Ion Exchange Chromatography

With its origins in the 1940s Nobel Prize-winning work of Moore and Stein (Moore et al., 1956), who separated amino acids on derivatized beads of polystyrene cross-linked with divinylbenzene, ion exchange is the most well-known and traditional method of protein chromatography. (Kovacs & Guttman, 2013; Vasileva et al, 1981; Abdolalizadeh et al, 2008; Maleki and al, 2013) IEC frequently processes albumin and other proteins. 

The anion exchange approach is the one that is used the most frequently among them (Vasiliva et al., 1981). 

The procedure consists of three steps. Pre-treatment, polishing, and filtration are typical IEC processes. Most individuals are aware of the shortcomings of conventional chromatography methods, which include extended processing times, restricted flow rates, and other issues. 

Improved adsorbers served as the foundation for the development of a revolutionary ion exchange membrane chromatography (IEM) technique that addressed these problems (Frerick et al., 2006). Simulation tests were carried out to compare the IEM with the IEC (Frerick et al., 2008). 




Chromatography Evaluation using SDS-PAGE Analysi

The purity of the fractions from the IEC was assessed by affinity chromatography under reducing conditions using the traditional Laemmeli technique in conjunction with SDS-PAGE. The separating gel had 12% polyacrylamide concentration, while the stacking gel had 4%. The electrophoresis procedure was carried out using the mini-PROTEAN electrophoresis apparatus, which is produced in the United States by Bio-Rad Laboratories. The protein bands were identified using CBB R-250 (Raoufinia et al., 2016).

Heat Shock Method

The heat shock purification method can be used to purify albumin since it is more stable under temperature changes than other plasma proteins. Because of this, the albumin protein is resistant to heat up to 60 degrees Celsius, which may render a potential infection inactive (Raoufinia et al., 2016). Serum albumin was stabilised at 60 °C in pH 5 using 0.04 caprylic acid. In this state, additional serum proteins get denatured and precipitate as a liquid. After that, precipitation and ultrafiltration are used to concentrate albumin until a purity of roughly 98% is reached (Denizli, 2011).




Critical Analysis

Albumin is an abundant protein in the body. Albumin has a major function in Nutrition, balancing osmotic pressure; maintaining iron deficiency and transport of body fluids. Albumin has a very important role in the research and industrial level and there will be a sharp increase in the market of albumin due to the latest outbreak of coronavirus. In terms of albumin protein preference, various methods for albumin purification were applied; the above methods such as purification by Precipitation using ammonium sulfate salt, ion exchange chromatography, affinity chromatography, through GFC and heat shock method. These all methods have their own importance, effectiveness and cost.

Conclusion

In this article, we developed a concise overview of albumin, its market value and purification techniques of albumin.

References

• Suri, S. S. H., &Fenniri, B. (2007) Singh, Nanotechnology-based drug delivery systems, J.Occup. Med. Toxicol. 1, 2–16.
• Roco, M. C. (2003). Nanotechnology: convergence with modern biology and medicine, Curr. Opin. Biotechnol. 14, 337–346.
• Torchilin, V. P. (2008). Nanotechnology in Drugs, second ed. Imperial College Press,London,
• Sahoo, S. K. V. (2008). Labhasetwar, Nanotech approaches to drug delivery and imaging, Drug Discov. Today 8, 1112–1120
• Couvreur, P. C. (2006). Vauthier, Nanotechnology: intelligent design to treat complex disease, Pharm. Res. 23, 1417–1450.
• Kumar, R. M. N. (2000). Nano and microparticles as controlled drug delivery devices, J.Pharm. Pharm. Sci. 3, 234–258
• Liu, Z, Y. Jiao, Y. Wang, C. Zhou, Z. Zhang. (2008). Polysaccharides-based nanoparticles as drug delivery systems, Adv. Drug Deliv. Rev. 60, 1650–1662
• Fernandez-Urrusuno, P., Calvo, C., Remunan- Lopez, J., L. & Vila-Jato, M. J. (1999). Alonso, Enhancement of nasal absorption of insulin using chitosan nanoparticles, Pharm. Res. 16, 1576–1581
• Farrugia, M. J. (1999). Groves, the activity of unloaded gelatin nanoparticles on murine B16-F0 melanoma growth in vivo, Anticancer. Res. 19, 1027–1031
• Fattal, C. Vauthier, I. Aynie, Y. Nakada, G. Lambert, C. Malvy, P. (1998). Couvreur, Biodegradable polyalkylcyanoacrylate nanoparticles for the delivery of oligonucleotides, J. Control. Release 53, 137– 143.
• Breunig, S. Bauer, A. (2008). Goepferich, Polymers and nanoparticles: intelligent tools for intracellular targeting? Eur. J. Pharm. Biopharm. 68, 112–128.
• Kuijpers, P.B. van Wachem, M.J.A. van Luyn, L.A. Brouwer, G.H.M. Engbers, J. Krijgsveld, (2000). In vitro and in vivo evaluation of gelatin chondroitin sulphate hydrogels for controlled release of antibacterial proteins, Biomaterials 21, 1763–1772
• Elzoghby, W.S. Abo El-Fotoh, N. A. (2011). Elgindy, Casein-based formulations as promising controlled release drug delivery systems, J. Control. Release 153, 206–216.
• Vandelli, F. Rivasi, P. Guerra, F. Forni, R. (2001). Arletti, Gelatin microspheres crosslinked with d, l-glyceraldehyde as a potential drug delivery system: preparation, characterization, in vitro and in vivo studies, Int. J. Pharm. 215, 175–184.
• Sahin, H. Selek, G. Ponchel, M.T. Ercan, M.A. Sargon, A. Hincal, H.S. (2002). Kas, Preparation, characterization and in vivo distribution of terbutaline sulfate loaded albumin microspheres, J. Control. Release 82, 345–358.
• Langer, S. Balthasar, V. Vogel, N. Dinauer, H. von Briesen, D. (2003). Schubert Optimization of the preparation process for human serum albumin (HSA) nanoparticles, Int. J. Pharm. 257, 169–180.
• Rubino, R. Kowalsky, J. (1993). Swarbrick, Albumin microspheres as a drug delivery system: relation among turbidity ratio, degree of cross-linking and drug release, Pharm. Res. 10, 1059–1065.
• Kommareddy, M. (2005). Amiji, Preparation and evaluation of thiol-modified gelatin nanoparticles for intracellular DNA delivery in response to glutathione, Bioconjug. Chem. 16, 1423–1432.
• Azarmi, X. Tao, H. Chen, Z. Wang, W.H. Finlay, R. (2006). Löbenberg, W.H. Roa, Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles, Int. J. Pharm. 319, 155–161.
• Kratz, I. Fichtner, P. Schumarcher, T. (1997). Roth, H.H. Feibig, C. Unger, Antitumoractivity of acid labile transferrin and albumin doxorubicin conjugates in vitro and in vivo human tumor xerograft models, Eur. J. Cancer 33, S175
• Rahimnejad, M. Jahanshahi, G.D. (2006). Najafpour, Production of biological nanoparticles from bovine serum albumin for drug delivery, Afr. J. Biotechnol.5, 1918–1923
• Fasano, M., Curry, S., & Terreno, E. (2005). The extraordinary ligand binding properties human serum albumin. IUBMB Life 57, 787– 79
• Droge, W., Schulze-Osthoff, K., & Mihm, S, (1994). Functions of glutathione and glutathione disulfide in immunology and immunopathology. FASEB J, 8, 1131–1138
• Stohl, W. (1996). Elliot JE: In vitro inhibition by intravenous immunoglobulin of human cell- dependent B cell differentiation induced by staphylococcal superantigens. Clin Immunol Immunopathol, 79, 122–133
• Stohl, W. (1996). Elliot JE: In vitro inhibition by intravenous immunoglobulin of human cell- dependent B cell differentiation induced by staphylococcal superantigens. Clin Immunol Immunopathol, 79, 122–133
• Ephrem, A., Chamat, S., & Miquel, C, (2008). Expansion of CD4+ CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood, 111, 715–722
• Kragh-Hansen, U. (2013). Molecular and practical aspects of the enzymatic properties of human serum albumin and of albumin-ligand complexes. Biochim Biophys Acta , 1830(12), 5535-44
• Elzoghby, A. O., Samy, W. M., & Elgindy, N. A. (2012). Albuminbased nanoparticles as potential controlled release drug delivery systems. J Control Release, 157(2), 168-82.
• Liumbruno, G. M., Bennardello, F., Lattanzio, A., Piccoli, P., & Rossettias, G. (2009). Recommendations for the use of albumin and immunoglobulins. Blood Transfus, 7(3):216- 34
• Dugaiczyk, A., Law, S. W., & Dennison, O. E. (1982). Nucleotide sequence and the encoded amino acids of human serum albumin mrna. Proc Natl Acad Sci USA , 79(1):71-5.
• Clowes, G. H. J., Vucinic, M., & Weidner, M. G. (1966). Circulatory and metabolic alterations associated with survival or death in peritonitis: Clinical analysis of 25 cases. Ann Surg, 163(6):866-85
• Chen, Z., He, Y., Shi, B., & Yang, D. (2013). Human serum albumin from recombinant DNA technology:Challenges and strategies. Biochim Biophys Acta, 1830(12):5515-25
• Chen, Z., He, Y., Shi, B., & Yang, D. (2013). Human serum albumin from recombinant DNA technology:Challenges and strategies. Biochim Biophys Acta, 1830(12):5515-25
• Raoufinia, R., Mota, A., Nozari, S., Aghebati, M. L., Balkani, S., & Abdolalizadeh, J. (2016). A methodological approach for purification and characterization of human serum albumin. J Immunoassay Immunochem, 37(6):623-35
• He, Y., Ning, T., Xie, T., Qiu, Q., Zhang, L., & Sun, Y. (2011). Large-scale production offunctional human serum albumin from transgenic rice seeds. Proc Nat Acad Sci USA, 108(47):19078- 83
• Raoufinia, R., Mota, A., Nozari, S., Aghebati, M. L., Balkani, S., & Abdolalizadeh, J. (2016). AMethodological Approach for Purification and Characterization of Human Serum Albumin.J. Immunoassay Immunochem. 37(6), 623–635
• Hage, D. S., Anguizola, J. A., Bi, C., Li, R., Matsuda, R., & Papastavros, E, (2012). Pharmaceutical and biomedical applications of affinitychromatography: Recent trends and developments. J Pharm Biomed Anal, 69, 93- 105
• Abdolalizadeh, J., Nouri, M., Zolbanin, J. M., Barzegari, A., Baradaran, B., & Barar, J. (2013). Targeting cytokines: Production and characterization of antiTNF-alpha scFvs by phage display technology. Curr Pharm Des, 19(15), 2839-47
• Abdolalizadeh, J., Majidi, Z. J., Nouri, M., Baradaran, B., Movassaghpour, A., & Farajnia, S. (2013). Affi nity purification of tumor necrosis factoralpha expressed in raji cells by Produced scFvantibody coupled CNBr-activated sepharose. Adv Pharm Bull, 3(1):1923.
• Abdolalizadeh, J., Nouri, M., Zolbanin, J. M, Baradaran, B., Barzegari, A., & Omidi, Y. (2012). Downstream characterization of anti- TNF-alpha single chain variable fragment antibodies. Hum Antibodies, 21(1-2), 41-8
• Cuatrecasas, P., Wilchek, M., & Anfinsen, C. B. (1968). Selective enzyme purification byaffinity chromatography. Proc Natl Acad Sci USA, 61(2), 636-43.
• Moore, S., & Stein, W. H. (1956). Column chromatography of peptides and proteins. Adv. Protein Chem., 11, 191-236.
• William, W. (2009). Ward and Gavin Swiatek, Protein Purification, Current Analytical Chemistry, 5,000-000
• Kovacs, A., & Guttman, A. (2013). Medicinal chemistry meets proteomics: Fractionation of the human plasma proteome. Curr Med Chem, 20(4), 483-90.
• vasileva, R., Jakab, M., & Hasko, F. (1981). Application of ionexchange chromatography for the production of human albumin. J Chromatogr, 216, 279-84.
• Abdolalizadeh, J., Majidi, J., & Farajnia, S. (2008). Production and purification of polyclonal antibody against human kappa light chain. J Biol Sci, 8(3), 683-6.
• Aghebati, M. A. (2013). Large scale generation and characterization of anti-human cd34 monoclonal antibody in ascetic fluid of balb/c mice. Adv Pharm Bull, 3(1), 211-6.
• Frerick, C., Kreis, P., Gorak, A., & Melzner, D. (2006). Simulation and optimisation of the downstream process for purification of human serum albumin by using ion exchange membrane adsorbers. Desalination, 200 (1-3), 468-9
• Frerick, C., Kreis, P., Gorak, A., Tappe, A., & Melzner, D. (2008). Simulation of a human serum albumin downstream process incorporating ion-exchange membrane adsorbers. Chem Eng Process, 47(7), 1128-38
• Ramin, R., Ali, M., Neda, K., Fatemeh, S., Sara, S., & Jalal, A. (2016). Overview of protein ad its purification. Adv pharm bull, 6(4), 495-507.
• Denizli, A. (2011). Plasma fractionation: Conventional and chromatographic methods for albumin purification. Hacettepe J Biol Chem 39(4), 315-41.